SPECIAL FEATURE – PFS & Parenteral Manufacturing: How COVID-19 Changed the Market

Through insightful scientific, business, news, and technology-related formats, Drug Development & Delivery provides pharmaceutical professionals with practical solutions to the issues, opportunities, and challenges in the ever-evolving drug development communities.

With the continued growth in both biologics and biosimilars for subcuta­neous delivery, these formulations present challenges related to the volume of injection, viscosity, and injection time. Hence, there is an increased need to deliver higher volumes of bi­ologics (greater than 1mL) via subcu­taneous injection. This has led to the emergence of safety devices for 2.25mL PFS, enabling higher volume administration and the benefit of preventing needlestick injuries as well as enabling patients to administer medication at home. Get the full story here.